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Background: The course of cognitive function in first-episode psychosis (FEP) patients
suggests that some individuals are normal or near normal whereas some cases present a
marked decline.The goal of the present longitudinal study was to identify neuroanatomical
differences between deficit and non-deficit patients.
Methods: Fifty nine FEP patients with neuroimage and neurocognitive information were
studied at baseline and 3 year after illness onset. A global cognitive function score was
used to classify deficit and non-deficit patients at baseline. Analysis of covariances and
repeated-measures analysis were performed to evaluate differences in brain volumes. Age,
premorbid IQ, and intracranial volume were used as covariates.We examined only volumes
of whole brain, whole brain gray and white matter, cortical CSF and lateral ventricles, lobular
volumes of gray and white matter, and subcortical (caudate nucleus and thalamus) regions.
Results:At illness onset 50.8% of patients presented global cognitive deficit.There were no
significant differences between neuropsychological subgroups in any of the brain regions
studied at baseline [all F (1, 54)≤3.42; all p≥0.07] and follow-up [all F (1, 54)≤3.43; all
p≥0.07] time points. There was a significant time by group interaction for the parietal tis-
sue volume [F (1, 54)=4.97, p=0.030] and the total gray matter volume [F (1, 54)=4.31,
p=0.042], with the deficit group showing a greater volume decrease.
Conclusion: Our results did not confirm the presence of significant morphometric dif-
ferences in the brain regions evaluated between cognitively impaired and cognitively
preserved schizophrenia patients at the early stages of the illness. However, there were
significant time by group interactions for the parietal tissue volume and the total gray mat-
ter volume during the 3-year follow-up period, which might indicate that cognitive deficit in
schizophrenia would be associated with progressive brain volume loss.
Keywords: first-episode psychosis, neuroanatomical, neurocognition, schizophrenia, cognitive deficit
INTRODUCTION
Cognitive deficits are core features of schizophrenia that are
already evident at early phases of the illness (1, 2), with more than
80% of patients showing deficits in one or more domains of cogni-
tive function (3). There are, however, noticeable differences among
patients, with a subgroup showing severe and debilitating cogni-
tive dysfunctions, typical of Kraepelin’s description of dementia
praecox (4), and other subgroup considered to be “neuropsycho-
logically normal” (5). These distinguishable subgroups probably
lie at different levels of severity on a continuum of causes or of
different factors that might be influencing outcome (6).
Cognitive functioning has been associated with measures
of brain structures both in schizophrenia patients and healthy
subjects (7). It is now well established that schizophrenia is also
associated with structural brain abnormalities (8, 9). Although
some longitudinal magnetic resonance imaging (MRI) studies
have reported a progressive brain tissue loss during the early years
after the first psychotic episode of schizophrenia compared to
healthy subjects (10–12), others have failed to reveal such pro-
gressive brain volume loss (13–18). Nevertheless, only few studies
have examined those brain abnormalities that characterize the dis-
order in cognitive subgroups and, to the best of our knowledge,
there are no previous studies that have examined progressive brain
changes associated with cognitive deficit in schizophrenia.
The aim of this study was to identify neuroanatomical dif-
ferences that possibly underlie neurocognitive function deficit in
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first-episode psychosis (FEP) patients followed up for 3-years. Pre-
vious studies have associated white matter abnormalities with cog-
nitive deficit (19, 20). Perez-Iglesias and colleagues (19), using dif-
fusion tensor imaging, showed that deficits in executive and motor
functioning in patients with FEP were associated with reductions
in white matter integrity, and Wexler et al. (20) found that neu-
ropsychologically impaired patients had significantly smaller white
matter volumes in several regions. On the basis of these studies,
we hypothesized that patients with cognitive deficit would present
a white matter volume diminution.
MATERIALS AND METHODS
STUDY DESIGN AND SETTING
Data for the present investigation were obtained from a large epi-
demiological and 3-year longitudinal intervention program of FEP
(PAFIP) conducted at the outpatient clinic and the inpatient unit at
the University Hospital Marques de Valdecilla, Santander, Spain.
It conformed to international standards for research ethics and
was approved by the local institutional review board. Informed
consent of the participants was obtained after the nature of the
procedures had been fully explained. The referrals to the PAFIP
came from the inpatient unit and emergency room at the Uni-
versity Hospital Marques de Valdecilla, community mental health
services and other community health care workers in Cantabria.
A more detailed description of our program has been previously
reported (21, 22).
SUBJECTS
All the patients included in PAFIP from February 2001 to Decem-
ber 2007 were invited to participate in this study. Patients referred
to the program were selected if they met the following criteria:
(1) 15–60 years; (2) living in the catchment area; (3) experienc-
ing their first-episode of psychosis; (4) no prior treatment with
antipsychotic medication or, if previously treated, a total life time
of adequate antipsychotic treatment of less than 6 weeks; (5) DSM-
IV criteria for brief psychotic disorder, schizophreniform disorder,
schizophrenia, or schizoaffective disorder. Patients were excluded
for any of the following reasons: (1) meeting DSM-IV criteria
for drug dependence, (2) meeting DSM-IV criteria for mental
retardation, (3) having a history of neurological disease or head
injury. Our operational definition for a“first-episode of psychosis”
included individuals with a non-affective psychosis (meeting the
inclusion criteria defined above) who have not received previ-
ously antipsychotic treatment regardless the duration of psychosis.
Individuals who entered the study received extensive clinical
and psychopathological assessments and were examined by MRI
scan. Only those patients who had a baseline neuropsychologi-
cal assessment and completed both baseline and 3-year follow-up
MRI scans were included in this study. Thus, 59 patients with a
schizophrenia-spectrum disorder (schizophrenia N = 37, 62.7%;
schizophreniform disorder, N = 15, 25.4%; schizoaffective dis-
order, N = 2, 3.4%; brief psychotic disorder, N = 2, 3.4%; not
otherwise specified psychosis, N = 3, 5.1%) were included in the
study.
The diagnoses were confirmed using the Structured Clinical
Interview for DSM-IV (SCID-I) (23) carried out by an experienced
psychiatrist 6 months after the baseline visit.
A group of healthy subjects (N = 43) who had no current
or past history of psychiatric illness, including substance depen-
dence, neurological or general medical disorders, as determined
by using an abbreviated version of the Comprehensive Assess-
ment of Symptoms and History (CASH) (24), was recruited from
the local area. The controls underwent the same cognitive bat-
tery as the patients. After a detailed description of the study, each
healthy subject gave their written informed consent to participate,
in accordance with the local ethics committee (25).
There were no significant differences in a variety of variables
(e.g., age at baseline, age of onset, academic level, alcohol, cannabis,
or tobacco consumption, duration of untreated psychosis (DUP),
duration of untreated illness (DUI), or symptomatology factors)
between patients who were and those who were not included in
the final analysis (all p> 0.236).
CLINICAL ASSESSMENT
Clinical symptoms were assessed by using the Brief Psychiatric
Rating Scale total (BPRS) (26), the Scale for the Assessment of Neg-
ative Symptoms (SANS) (27), and the Scale for the Assessment of
Positive Symptoms (SAPS) (28). We also divided psychopathology
into three dimensions of symptoms: positive (scores for halluci-
nations and delusions), disorganized (scores for formal thought
disorder, bizarre behavior, and inappropriate affect), and negative
(scores for alogia, affective flattening, apathy, and anhedonia) (29).
PREMORBID AND SOCIODEMOGRAPHIC VARIABLES
Premorbid and sociodemographic information was recorded from
patients, relatives, and medical records. Age of onset of psychosis
was defined as the age when the emergence of the first continuous
(present most of the time) psychotic symptom occurred. DUI was
defined as the time from the first unspecific symptoms related to
psychosis (for such a symptom to be considered, there should be
no return to previous stable level of functioning) to initiation of
adequate antipsychotic drug treatment. DUP was defined as the
time from the first continuous (present most of the time) psychotic
symptom to initiation of adequate antipsychotic drug treatment.
Information about alcohol, cannabis, and tobacco consume were
converted into binary variables coding for either the presence or
absence of use.
MEDICATION ASSESSMENT
The amount and type of medication being prescribed during the
3-year follow-up period was thoroughly recorded. Patients were
randomized as part of an intervention program out of the scope
of the present study. After written informed consent was obtained,
patients were randomly assigned to Haloperidol (N = 8), Olan-
zapine (N = 12), Risperidone (N = 12), Quetiapine (N = 8),
Ziprasidone (N = 10), and Aripiprazole (N = 9). At 3-year follow-
up patients were on: Haloperidol (N = 3), Olanzapine (N = 8),
Risperidone (N = 12), Quetiapine (N = 5) Ziprasidone (N = 4),
Aripiprazole (N = 8), Amisulpride (N = 1), Clozapine (N = 2),
and Risperidone depot (N = 4). Eight patients withdrew from the
medication, 27 patients switched their medication during follow-
up period, and 2 were taking more than one antipsychotic at
the time of follow-up MRI. No reliable information on medica-
tion intake was available for four patients. Additional information
about concomitant medications is available under request.
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NEUROPSYCHOLOGICAL ASSESSMENT
For the present study, baseline neuropsychological assessment was
considered in both groups, patients, and normal control sub-
jects. Baseline patients’ assessment was carried out when clin-
ical status permitted in order to maximize cooperation, and
occurred at a mean of 10.5 weeks after intake followed by assess-
ment after 3 years. They were never assessed during a period of
clinical exacerbation. A detailed description has been reported
elsewhere (1).
For the analysis in this study a subset of measures was selected
to assess eight major cognitive domains: (1) for measuring ver-
bal memory we used the Rey Auditory Verbal Learning Test
[RAVLT (30)], delayed recall; (2) for measuring visual memory
we used Rey Complex Figure [RCF (31)], delayed reproduc-
tion; (3) for measuring executive functions we used Trail Making
Test [TMT (32)], time to complete TMT-B; (4) for measur-
ing working memory we used the Backward Digits scale [WAIS
III (33)], total subscore; (5) for measuring speed of processing
we used WAIS III subtest Digit Symbol, standard total score;
(6) for motor dexterity we used Grooved Pegboard Handedness
(34), time to complete with dominant hand; (7) for measur-
ing attention we used Continuous Performance Test [CPT (35)],
total number of correct responses; (8) The WAIS III subtest of
Vocabulary was used as measure of premorbid IQ (34), standard
total score.
In order to calculate a measure of Global Cognitive Function-
ing (GCF), raw cognitive scores were reversed when appropriate
before standardization so they all have the same direction (the
higher, the better). According to previous methodology (36), the
GCF was calculated as T -scores (mean= 50, SD= 10) with raw
scores of the healthy comparison sample. T -scores were con-
verted to deficit scores that reflect presence and severity of cog-
nitive deficit. Deficit scores on all tests were then averaged to
create the GCF, which according to Keefe and colleagues deficit
criterion (37), was dichotomized into two patients’ subgroups:
“deficit” (GCF <1) and “non-deficit” (GCF ≥1) [see Ref. (6) for
details].
MRI DATA ACQUISITION
A multimodal MRI protocol [T1, T2, and proton density
(PD) sequences] was acquired at the University Hospital Mar-
ques de Valdecilla, Santander, Spain, using a 1.5-T General
Electric SIGNA System (GE Medical Systems, Milwaukee, WI,
USA). This multimodal approach was designed to optimize
discrimination between gray matter, white matter, and cere-
brospinal fluid. The T1-weighted images, using a spoiled grass
(SPGR) sequence, were acquired in the coronal plane with
the following parameters: echo time (TE)= 5 ms, repetition
time (TR)= 24 ms, number of excitations (NEX)= 2, rota-
tion angle= 45°, field of view (FOV)= 26 cm× 19.5 cm, slice
thickness= 1.5 mm, and a matrix of 256× 192. The PD and
transverse relaxation time (T2)-weighted images were obtained
with the following parameters: 3.0 mm thick coronal slices,
TR= 3000 ms, TE= 36 ms (for PD) and 96 ms (for T2), NEX= 1,
FOV= 26 cm× 26 cm, matrix= 256× 192. The in-plane resolu-
tion was 1.016 mm× 1.016 mm. MRIs of patients and controls
were evenly acquired during follow-up time.
IMAGE PROCESSING
Processing of the images after acquisition was done by using
a family of software programs called BRAINS2 (38, 39). The
T1-weighted images were spatially normalized and resampled to
1.0-mm3 voxels so that the anterior-posterior axis of the brain
was realigned parallel to the anterior commissure/posterior com-
missure line and the interhemispheric fissure aligned on the
other two axes. The T2- and PD-weighted images were then
aligned to the spatially normalized T1-weighted image. These
images were then subjected to a linear transformation into stan-
dardized stereotaxic Talairach atlas space to generate automated
measurements of frontal, temporal, parietal, and occipital lobes
and also the cerebellum and subcortical regions (39). To fur-
ther classify tissue volumes into gray matter, white matter, and
CSF, we used a discriminant analysis method of tissue segmen-
tation based on automated training class selection that utilized
data from the T1-weighted, T2-weighted, and PD sequences (40).
The discriminant analysis method permits to identify the range
of voxel intensity values that characterize GM, WM, and CSF.
An 8 bit number is assigned to each voxel indicating its par-
tial volume tissue content (10–70 for CSF, 70–190 for GM, and
190–250 for WM). In this study we examined the volumes of
whole brain (WB), whole brain gray matter (WBGM), whole brain
white matter (WBWM), cortical CSF (CCSF), and lateral ventri-
cles (LV), gray and white matter volumes of cortical (occipital,
parietal, temporal, and frontal lobes) and subcortical (caudate
nucleus and thalamus) regions volume. Caudate and thalamus
were delineated using a reliable and validated semiautomated
artificial neural network (41). The procedure for measuring the
volume of caudate and thalamus are explained in detail in previous
studies (42, 43).
STATISTICAL ANALYSIS
The Statistical Package for Social Science, version 19.0 (SPSS Inc.,
Chicago, IL, USA), was used for statistical analyses. Significance
was determined at the 0.05 level.
To examine brain volumetric differences between neurocog-
nitive subgroups (no deficit vs. deficit) at baseline and 3-year
follow-up, 1-way ANCOVA was performed. In each general lin-
ear model, the dependent measures were MRI volumes and the
independent measure was group (no deficit vs. deficit). To test
the hypothesis that the two groups would result in different
progressive brain volume changes, repeated-measures analysis of
covariance (repeated-measures ANCOVA) was performed for each
ROI variable. The between-subject factor was group (no deficit
vs. deficit) and the within subject factor was time (baseline and
3 year). Effects of time by group (interaction effect) were exam-
ined. Age, ICV, and premorbid IQ were included as covariates.
There were no differences between groups related to age and ICV.
However, there was a wide age range in our sample and the use
of these two variables has been suggested in brain volume studies
(44). The sample size (n= 59) provided sufficient power (>80%)
to detect large effect sizes (dCohen > 0.8) but was underpowered
(45%) to detect weak or modest effects (dCohen < 0.5).
Pearson correlation coefficients with age, ICV, and IQ as covari-
ates were used to investigate possible statistical relationships
between brain volume and GCF.
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A prior directional hypothesis had been made for the brain
measure analyses, thereby lessening the need for Bonferroni
corrections. The analyses examining the relationships between
brain measures and GCF were performed without prespecified
hypotheses, and therefore Bonferroni adjustments were applied.
RESULTS
Demographic and clinical data are shown in Table 1. Neuropsy-
chological baseline assessment showed that of the 59 patients
included in the study, 30 (50.8%) presented general neurocognitive
deficit. There were no statistically significant differences in relevant
demographic and clinical characteristics between patients with
neurocognitive deficit (N = 30) and patients without it (N = 29)
at baseline (Table 1). However, the general neurocognitive deficit
group showed a significant higher BPRS total score and greater
severity of positive (SAPS total and positive dimension) and dis-
organized (scores for formal thought disorder, bizarre behavior,
and inappropriate affect) symptoms at follow-up.
Neuropsychological data is presented in Table 2. The gen-
eral neurocognitive deficit group had worse premorbid IQ, and
showed consistently greater deficits all over cognitive domains.
Worse executive function, poor motor dexterity, and particularly
attentional deficits marked the more severely deficit patients.
Brain volumes at baseline in FEP subjects are presented in
Table 3. There were no significant differences between neuropsy-
chological subgroups in any of the brain regions studied at base-
line [all F(1, 54)≤ 3.42; all p≥ 0.070] and follow-up [all F(1,
54)≤ 3.43; all p≥ 0.07] time points (Table 3). Patients with cog-
nitive deficit showed overall lower gray and white matter volumes
but these differences did not reach statistical significance.
There was a significant time by group interaction for the pari-
etal tissue volume [F(1, 54)= 4.97, p= 0.030], with the general
Table 2 | Comparison of neurocognitive groups on neuropsychological
variables (Student’ s t -distribution with 58 degrees of freedom).
Characteristics Non-deficit
(N =29)
Deficit
(N =30)
Statistics
Premorbid IQ −0.08 (1.13) −1.03 (1.19) t =3.07, p=0.003
Attention −0.39 (1.5) −4.41 (5.31) t =3.98, p<0.001
Verbal memory −0.73 (1.08) −1.31 (1.08) t =2.04, p=0.046
Visual memory −0.47 (1.1) −1.16 (1.09) t =2.41, p=0.019
Working memory −0.23 (0.51) −0.84 (0.75) t =3.66, p=0.001
Executive function −0.21 (0.74) −2.51 (2.56) t =4.72, p=0.001
Processing speed −1.02 (1.15) −2.02 (0.89) t =3.75, p=0.001
Table 1 | Sociodemographic and clinical characteristics of the two neurocognitive groups of patients.
Characteristics Non-deficit (N =29) Deficit (N =30) Statistics
Age at initial MRI, mean (SD), years 28.50 (6.93) 32.12 (9.97) F (1, 57)=2.59, p=0.113
ICV, mean (SD) 1367.41 (128.78) 1343.19 (120.18) F (1, 57)=0.56, p=0.458
Males, N (%) 18 (62.1) 20 (66.7) χ2(1)=1.36, p=0.712
Time between scans, mean (SD), (range) days 1117.96 (39.58) 1120.63 (56.34) F (1, 57)=0.04, p=0.835
Right-handed, N (%) 26 (89.7) 25 (83.3) χ2(1)=0.50, p=0.478
Parental socioeconomic status, mean (SD) 3.45 (0.87) 3.60 (0.89) F (1, 57)=0.44, p=0.512
Years of study, mean (SD) 10.89 (3.17) 10.13 (3.19) F (1, 57)=0.85, p=0.360
Alcohol users, N (%) 17 (58.6) 19 (63.3) χ2(1)=1.38, p=0.711
Cannabis users, N (%) 15 (51.7) 11 (36.7) χ2(1)=1.35, p=0.244
Tobacco users, N (%) 17 (58.6) 16 (53.3) χ2(1)=0.17, p=0.683
Age at onset, mean (SD), years 27.61 (6.28) 30.59 (9.79) F (1, 57)=1.91, p=0.172
DUP mean, (SD), (median), months 10.74 (19.39) 18.35 (21.15) F (1, 57)=2.07, p=0.155
DUI mean, (SD), (median), months 28.32 (32.79) 30.45 (29.54) F (1, 57)=0.07, p=0.794
SANS at intake, mean (SD) 6.55 (4.95) 7.13 (5.37) F (1, 57)=0.19, p=0.667
SANS at follow up, mean (SD) 1.89 (2.96) 3.34 (4.57) F (1, 55)=2.00, p=0.162
SAPS at intake, mean (SD) 13.44 (4.44) 13.67 (4.17) F (1, 57)=0.04, p=0.846
SAPS at follow up, mean (SD) 0.57 (1.40) 2.86 (4.62) F (1, 55)=6.30, p=0.015
BPRS at intake, mean (SD) 62.00 (11.67) 63.50 (13.68) F (1, 57)=0.21, p=0.653
BPRS at follow-up, mean (SD) 27.14 (4.33) 32.93 (14.17) F (1, 55)=4.28, p=0.043
SYMPTOM DIMENSIONSTOTAL SCORES AT BASELINE
Negative (mean) (SD) 4.75 (4.69) 5.40 (4.90) F (1, 57)=0.26, p=0.610
Disorganized (mean) (SD) 6.07 (3.43) 6.10 (3.35) F (1, 57)<0.01, p=0.972
Psychotic (mean) (SD) 7.37 (2.38) 7.57 (2.31) F (1, 57)=0.09, p=0.760
SYMPTOM DIMENSIONSTOTAL SCORES AT FOLLOW UP
Negative (mean) (SD) 1.54 (2.33) 2.90 (4.25) F (1, 55)=2.23, p=0.141
Disorganized (mean) (SD) 0.25 (0.84) 1.45 (2.99) F (1, 55)=4.16, p=0.046
Positive (mean) (SD) 0.32 (1.19) 1.41 (2.06) F (1, 55)=5.95, p=0.018
BPRS, brief psychiatric rating scale; DUP, duration of untreated psychosis; DUI, duration of untreated illness; ICV, intracranial volume; SANS, scale for the assessment
of negative symptoms; SAPS, scale for the assessment of positive symptoms; SD, standard deviation. Bold values were statistically significant (p<0.05).
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FIGURE 1 |Total gray matter and parietal tissue volume in deficit and non-deficit first-episode psychosis patients.
neurocognitive deficit group showing a greater volume decrease
(1.67%) than the non-deficit group (0.13%). Similarly, there was
also a significant time by group interaction for the total gray matter
volume [F(1, 54)= 4.31, p= 0.042], showing a greater reduction
in the general neurocognitive deficit group (2.71%) than in the
non-deficit group (1.45%) (see Figure 1). Interestingly, when
the analyses were controlled by possible confounding variables
(sex, DUP, tobacco, cannabis, and alcohol consumption) only the
parietal lobe tissue showed a significant group by time interaction.
No significant correlations between brain volume at baseline
and GCF were found. At follow-up period, there were signifi-
cant negative correlations between GCF and parietal tissue lobe
(r =−0.29, p= 0.031) and temporal lobe gray matter (r =−0.27;
p= 0.049). However, these correlations were weak and did not
remain significant after correcting for multiple testing (Bonferroni
correction).
DISCUSSION
In the present study, a GCF index was calculated to identify schizo-
phrenia patients who had general neurocognitive deficit at baseline
(6). Contrary to our expectations, there were no brain volume
differences between the cognitively impaired and cognitively pre-
served groups at any of the time-point studied. However, there
were significant time by group interactions for the parietal tis-
sue volume and the total gray matter volume, with the general
neurocognitive deficit group showing a greater reduction in both
regions during the 3-year follow-up interval. This is, to the best
of our knowledge, the first study to examine progressive brain
changes in schizophrenic cognitive deficit.
Neuropsychological assessment carried out at baseline indi-
cated that 50.8% of the patients included in the study presented
general neurocognitive deficit. These results are in full agreement
with previous studies in FEP patients (2).
Only two previous cross-sectional studies (20, 45) have exam-
ined brain volume differences between cognitive subgroups in
schizophrenia and their results have been inconclusive. Supporting
our results, Ortiz-Gil and colleagues (45) did not find differences
in lateral ventricular volume or WB volume between cognitively
intact and cognitively deficit schizophrenia patients. Using Voxel-
based morphometry, they also failed to detect significant difference
in volumes of gray and white matter between those groups. How-
ever, Wexler et al. (20), using VBM to compare neuropsychology
near normal and neuropsychology impaired subgroups, found
that these groups differed significantly from each other in white
matter volumes of the sensorimotor and parietal-occipital regions,
with the neuropsychology impaired group showing smaller vol-
umes in these brain regions. Nonetheless, it is of note that this
VBM study did not adopt any statistical procedures to control for
multiple comparisons. It is important to take into account that
mean duration of illness among patients was above 18 years in
both studies, while our patients had a shorter duration of illness
(non-deficit: 28.32 months, deficit: 30.45 months).
Only cross-sectional studies have addressed the relationship
between cognitive deficit and brain structure in schizophrenia.
However, it has been suggested that this relationship may not be
adequately assessed in a cross-sectional study (45). We found sig-
nificant time by group interactions for the parietal tissue volume
and the total gray matter volume, with the general neurocognitive
deficit group showing a greater reduction in both regions (parietal
tissue volume and the total gray matter volume) during the 3-year
follow-up interval. In a recent study (13) we found that brain tissue
volumes decrease in patients at early years after the first episode
was similar to that found in healthy controls. Although several lon-
gitudinal studies in schizophrenia have described a greater degree
of brain tissue volumes decrease in the early stage of the illness
(10–12), others have failed to confirm these findings (13–18). For
a review see Olabi et al. (46). Taken this together, we might specu-
late that the progressive brain volume loss found in schizophrenia
might be associated with this general cognitive deficit patients’
subgroup.
LIMITATIONS
A uniform follow-up interval using the same MRI scanner and
protocol, and a thorough clinical investigation during the follow-
up period add strength to the conclusions drawn from this study.
However, several limitations should be taken into account when
interpreting the results of the current study. First, the diagnos-
tic heterogeneity of the sample might bias our findings. Second,
and given the fact that schizophrenia is a life-long disease, a
follow-up period of 3 years may be too short to demonstrate other
subtle changes. Third, analyses taking into account if neurocogni-
tive function maintained, declined, or improved during follow-up
could not be conducted because of the small sample size in our
study. Fourth, a major confounding factor could be the intake
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of antipsychotic medication (47). Some studies have showed a
relationship between antipsychotic medication use and longitu-
dinal brain volume change in schizophrenia (10, 48), although
others have failed to clearly demonstrate an influence of antipsy-
chotic medication on brain volume change (49–51). Some patients
withdrew from their medication, and most of them switched
medication during the 3-year follow-up period, which makes the
investigation of the effects of different types of antipsychotics
an unfeasible study. Fifth, this study only measured a number
of structures, and finally, brain volume changes in schizophrenia
are subtle, so the sample size might be considered small to make
any definitive assertions. While our data provided sufficient power
to detect large effects, the detection of weak effects requires large
study populations.
CONCLUSION
In conclusion, our results, based on a representative sample of first-
episode schizophrenia-spectrum patients, do not confirm the pres-
ence of significant morphometric differences between cognitively
impaired and cognitively preserved schizophrenia patients at the
early stages of the illness. However, there were significant time by
group interactions for the parietal tissue volume and the total gray
matter volume during the 3-year follow-up period, which might
indicate that cognitive deficit in schizophrenia would be associ-
ated with progressive brain volume loss. Further investigations are
warranted to fully clarify the relationship between cognitive deficit
and brain structure in schizophrenia.
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